|Title:|| Polyethylene glycol modified interferon therapy|
|Abstract:||A method comprising administering a PEG.sub.12000 -IFN alpha conjugate to an individual afflicted with a viral infection susceptible of treatment with interferon alpha, preferably chronic hepatitis C, is disclosed.|
|Inventor(s):|| Glue; Paul (Flemington, NJ), Cutler; David L. (Morristown, NJ), Affrime; Melton B. (Flemington, NJ) |
|Assignee:|| Schering Corporation (Kenilworth, NJ) |
1. A method for treating a patient suspected of having hepatitis C infection, comprising administering to the patient, in combination, (i) a conjugate comprising PEG.sub.12000
and interferon alpha-2b in an amount of from 0.5 .mu.g/kg to 2.0 .mu.g/kg, once or twice per week in single or divided doses, and (ii) ribavirin.
2. The method of claim 1 wherein the conjugate is administered in an amount of 0.5 .mu.g/kg twice per week.
3. The method of claim 1 wherein the conjugate is administered in an amount of 2.0 .mu.g/kg once per week.
4. The method of claim 1 wherein the conjugate is administered in an amount of 0.5, 1.0 or 1.5 .mu.g/kg once per week.